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AbstrACt
Introduction Osteonecrosis is a well-recognised 
treatment-related morbidity risk in patients diagnosed 
with acute lymphoblastic leukaemia (ALL) and 
lymphoblastic lymphoma (LBL), with a high rate of 
affected patients requiring surgical intervention. Patients 
may have asymptomatic changes on imaging studies 
that spontaneously regress, and little is known about 
the natural history of osteonecrotic changes seen. The 
main aim of the British OsteoNEcrosis Study (BONES) 
is to determine the incidence of symptomatic and 
asymptomatic osteonecrosis in the lower extremities of 
survivors of ALL or LBL diagnosed aged 10–24 years in 
the UK at different time points in their treatment. This 
study also aims to identify risk factors for progression 
and the development of symptomatic osteonecrosis in 
this population, as well as specific radiological features 
that predict for progression or regression in those with 
asymptomatic osteonecrosis
Methods and analysis BONES is a prospective, 
longitudinal cohort study based at principal treatment 
centres around the UK. Participants are patients aged 
10–24 years diagnosed with ALL or LBL under standard 
criteria. Assessment for osteonecrosis will be within 4 
weeks of diagnosis, at the end of delayed intensification 
and 1, 2 and 3 years after the start of maintenance 
therapy. Assessment will consist of MRI scans of the 
lower limbs and physiotherapy assessment. Clinical and 
biochemical data will be collected at each of the time 
points. Bone mineral density data and vertebral fracture 
assessment using dual-energy X-ray absorptiometry will 
be collected at diagnosis and annually for 3 years after 
diagnosis of malignancy.
Ethics and dissemination Ethical approval has been 
obtained through the Yorkshire and Humber Sheffield 
Research Ethics Committee (reference number: 16/
YH/0206). Study results will be published on the study 
website, in peer-reviewed journals and presented at 
relevant conferences and via social media.
trial registration number NCT02598401; Pre-results.
IntroduCtIon
Survival from acute lymphoblastic leukaemia 
(ALL) and lymphoblastic lymphoma (LBL) 
has steadily increased over the last 40 years 
so that the expected cure rate is now greater 
than 90% in children and young people 
presenting with ALL.1 This progress shifts the 
entire treatment paradigm so that the goal 
moves beyond cure to returning the young 
person to a normal life. The biggest barrier 
to this is the burden of treatment associated 
toxicity, and attention internationally is now 
beginning to focus on this issue. Osteone-
crosis (previously also referred to as avas-
cular necrosis, ischaemic necrosis and aseptic 
strengths and limitations of this study
 ► This study will be the first UK prospective study to 
obtain MRI within 4 weeks of diagnosis of   acute 
lymphoblastic leukaemia (ALL), with sequential im-
aging at four further time-points to assess progres-
sion or regression of osteonecrotic lesions.
 ► This study targets the most vulnerable patient pop-
ulation, those aged 10–24 years, who are at highest 
risk of development of symptomatic osteonecrosis.
 ► It will simultaneously assess multiple domains to 
correlate physical signs, symptoms and biological 
markers with MRI changes.
 ► This study is limited by the anticipated small sample 
size, which is due to the rarity of ALL and lympho-
blastic lymphoma in patients over 10 years of age, 
and prospective imaging of lower extremities only.
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necrosis) can be a devastating complication of treatment 
in older children and teenagers treated for ALL and can 
cause significant long-term morbidity.2 However, despite 
increasing concern about osteonecrosis, our under-
standing of it in the context of ALL or LBL is limited. 
Historically, information about osteonecrosis has not 
been well captured in previous studies of ALL, which 
partly reflects lack of good definitions and incomplete 
retrospective reporting.
Osteonecrosis occurs when there is bone ischaemia 
and infarction caused by temporary or permanent disrup-
tion to the blood supply and in ALL typically affects the 
femoral head, humeral head, knee, shoulder and ankles.2 
It is mostly an iatrogenic complication that has been 
attributed to increased use of glucocorticoids in treat-
ment of ALL.3 The role of other agents, such as high dose 
methotrexate4 and asparaginase,5 6 is uncertain. It has 
been reported that asparaginase reduces dexamethasone 
clearance and could potentiate the osteonecrotic effect 
of glucocorticoids.6 7 The cumulative dose of received 
glucocorticoids in patients with ALL has been shown to 
correlate with the risk of osteonecrosis,8 but there is no 
clear increase in osteonecrotic risk with the administra-
tion of either prednisolone or dexamethasone.8–11 Devel-
opment of osteonecrosis appears to be multifactorial but 
is seen more commonly in patients as survival improves 
and high dose steroids have become embedded in treat-
ment regimens.
Glucocorticoids predispose to the development of 
osteonecrosis in a number of ways, with proposed aetiol-
ogies including:
 ► Creation of a hypercoagulable state with endothelial 
cell apoptosis and development of microthrombi.
 ► Suppression of osteoblasts and apoptosis of osteocytes 
impairing the bone repair process.
 ► Stimulation of intramedullary lipocyte proliferation 
and hypertrophy resulting in increased intraosseous 
pressure.
These factors combine to compromise blood circula-
tion to the bone leading to cell death in a self-perpetu-
ating cycle.12
Interosseous fat emboli with intravascular coagulation 
and osteonecrosis has been described,13 with an over-
load of subchondral fat emboli, hypercoagulability, stasis 
and endothelial damage by free fatty acids hypothesised 
to cause end organ damage. Glucocorticoids-causing 
dyslipidaemia may promote the formation of fat emboli, 
although fat emboli are also found in healthy bones, 
which do not go on to develop osteonecrosis. The role of 
hypercoagulability is unclear. Some studies have shown 
procoagulant abnormalities in patients with osteone-
crosis,14 but the common thrombophilias have not been 
identified as risk factors for osteonecrosis, highlighting 
the multifactorial nature of the condition.
In one of the largest studies with prospective MRI 
screening to assess both symptomatic and asymptomatic 
osteonecrosis, the cumulative incidence of osteonecrosis 
involving the epiphysis or metaphysis of at least one 
hip was 17.1%±1.8% after early screening (1 year) and 
21.7%±1.9% after completion of therapy (4 years).15 By 
the end of therapy, extensive femoral head osteonecrosis 
affecting ≥30% of the epiphysial surface had developed 
in 6.5%±1.1% of all patients and 24%±4.4% of those aged 
over 10 years.15 The first findings of the osteonecrosis in 
pediatric patients with acute lymphoblastic leukaemia 
and lymphoblastic lymphoma (OPAL) trial, where MRI 
screening was at a median of 12.5 days, found leukaemic 
infiltrate at diagnosis was not associated with osteone-
crotic lesions16 but the point at which asymptomatic 
lesions develop remains unclear.
There are many more reports that rely on proac-
tive reporting to the study centre, with no prospec-
tive screening for asymptomatic osteonecrosis, and as 
expected, these tend to give a far lower prevalence of 
osteonecrosis, ranging from 0.67% to 15%.17–23
Age has consistently been identified as the most signif-
icant risk factor for development of symptomatic osteo-
necrosis, with the greatest incidence of osteonecrosis 
occurring in patients between 10 years and 20 years of age 
at diagnosis of ALL,2 22–27 a time of rapid skeletal growth. 
The pathogenesis that puts this group at highest risk of 
development of osteonecrosis is uncertain, although 
factors such as hormonal changes, skeletal maturation, 
osseous blood vessel supply, dexamethasone clearance 
and changes in concentrations of coagulation factors may 
all play a role.7 28
There is no clear consensus on risk differences 
with sex of the patient, with variation in study find-
ings.10 15 17 18 22 29–41 Inconsistent results have also been 
reported regarding the influence of increased body mass 
index (BMI) as a risk factor for development of osteo-
necrosis,15 32 34 40 41 and it is possible that varying thresh-
olds used for statistical analysis effect likelihood of BMI 
being found as a risk factor. One prospective study has 
reported a higher cumulative incidence of osteonecrosis 
in patients with higher increases in total cholesterol and 
triglycerides during therapy.42 White race was found to be 
a risk factor in a number of studies,25 33 35 but again this 
was inconsistent.15 24 Ethnicity as a risk factor is a difficult 
area to study due to a number of confounding factors, 
variation in terminology and differences in how ethnic 
groups are categorised.
Various genetic risk factors for the development of 
osteonecrosis have been identified. Genome-wide asso-
ciation studies indicate the glutamate receptor pathway 
to be of crucial importance, and single-nucleotide poly-
morphisms in adipogenesis pathways and in enhancers 
active in mesenchymal stem cells were also significantly 
associated with osteonecrosis development.35 43 Glucocor-
ticoid receptor binding sites have also been implicated in 
development of osteonecrosis.44
It is recognised that a significant percentage of changes 
on imaging studies identified as osteonecrosis may 
regress,24 although the reasons for this are not under-
stood. It is possible that some radiological changes inter-
preted as representing steroid-associated osteonecrosis 
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are in fact changes that have been present at diagnosis 
and that are a consequence of the original leukaemia.
Currently, the most widely used radiological classifi-
cation systems, such as the modified Ficat and Arlet,45 
use a multimodal approach combining scores for X-ray, 
MRI and in some cases bone scan findings. Most widely 
used classification systems were developed specifically for 
changes in the femoral head, in some cases over 20 years 
ago and in an entirely different patient population.45–49 
Further classifications systems have been developed more 
specifically for our patient population but as yet with no 
prognostic validation.50 This study will provide the data 
needed to develop and provide prognostic validation of a 
radiological classification system that correlates with clin-
ical status, as well as provide greater understanding of the 
natural history of bone lesions in patients being treated 
for ALL or LBL. Only once this is done can meaningful 
intervention studies be initiated.
treatment for uK patients with ALL or LbL
The majority of young people diagnosed with ALL or 
LBL between 26 April 2012 and 31 December 2018 
consented to be part of the national trial, UKALL 2011 
(ISRCTN64515327, Eudract 2010-020924-22), and treat-
ment for patients aged between 10 years and 25 years at 
diagnosis of ALL or LBL is described in figure 1. A list of all 
chemotherapeutic agents are available in online supple-
mentary file 1. Patients who did not consent to partici-
pate in UKALL2011, or who are diagnosed after the study 
closure, will receive the same treatment as those on the 
trial and at the point of randomisation receive standard 
interim or Capizzi interim maintenance, depending on 
their risk stratification. At the next randomisation point 
they receive maintenance therapy with vincristine/dexa-
methasone pulses and intrathecal methotrexate.
Postinduction treatment is determined by minimal 
residual disease (MRD) in ALL patients or tumour 
volume assessment in patients with LBL. Patients with no 
MRD results are assessed by morphology (% of blasts at 
day 8 of induction).
If a patient has been randomised to high dose metho-
trexate therapy, they will have no subsequent intrathecal 
methotrexate in maintenance but can be randomised to 
either pulses or no pulses. An exception to this is that 
patients with T cell ALL with white cell count >100×109 
cells/L at diagnosis who have an additional six doses of 
intrathecal methotrexate in maintenance. Pulses consist 
of vincristine and dexamethasone. If they have been 
randomised to either standard or Capizzi interim main-
tenance, they will be randomised to maintenance therapy 
with or without pulses, and all patients will receive intra-
thecal methotrexate.
Treatment will last 2 years from the start of interim 
maintenance for female patients, and 3 years from the 
start of interim maintenance for male patients. There are 
some treatment modifications for patients with Down’s 
syndrome to reduce toxicity.
objECtIvEs
The objective is to establish a prospective, multicentre 
study for older children, teenagers and young adults that 
can address the following questions:
 ► What is the incidence of symptomatic and asympto-
matic osteonecrosis in older children, teenagers and 
young adults being treated for ALL or LBL in the UK 
at different time points in their treatment?
 ► What are the risk factors for progression and the 
development of symptomatic osteonecrosis in this 
population?
Figure 1 UKALL 2011 trial schema for patients over the age of 10 (excluding patients with Down’s syndrome). BCP, B-cell 
precursor; BFM, Berlin-Frankfurt-Munich; LBL, lymphoblastic lymphoma; MRD, minimal residual disease; RER, rapid early 
response (<25% blasts at day 8 of induction); SER: slow early response (≥25% blasts at day 8 of induction). 
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 ► Are there specific radiological features that predict 
for either progression or regression in those with 
asymptomatic osteonecrosis?
The study also aims to:
 ► Evaluate functional ability as measured by the Child-
hood Health Assessment Questionnaire (CHAQ) and 
physiotherapy assessment and explore the correlation 
of this with MRI findings to start to establish validity of 
use in patients with osteonecrosis.
 ► Evaluate changes in bone mineral density and verte-
bral fracture incidence during treatment for ALL or 
LBL.
MEthods And AnALysIs
Details of the protocol, data collection forms, consent 
forms and patient information leaflets are available at 
http:// childhealth. leeds. ac. uk/ bones. html.
study design
Multicentre prospective longitudinal cohort study.
Patient and public involvement
Patients and families undergoing treatment or who had 
completed treatment for ALL or LBL were involved in the 
study design and in literature developed for patient infor-
mation by use of semistructured interviews. Patients were 
not involved in the recruitment to and conduct of the 
study. Results will be disseminated to study participants 
via the British OsteNEcrosis Study (BONES) website.
study setting
The BONES is conducted in principal treatment centres 
and teenage and young adult centres for patients with 
cancer within the UK. It is currently open in Leeds Chil-
dren’s Hospital; St James’s Hospital, Leeds; Birmingham 
Children’s Hospital; and Southampton Children’s 
Hospital. Additional centres, including Children’s 
Hospital for Wales, are in the research and development 
process.
dates of study
The first site opened to recruitment on 10 April 2017. 
The most recent centre to join opened to recruitment on 
22 March 2018. Additional sites are still in the process 
of opening the study. Recruitment is for a period of 2 
years from site opening or until a total of 50 patients are 
recruited.
study population
Inclusion criteria: children, teenagers or young adults 
between the age of 10 years and 24 years 364 days (at the 
time of diagnosis) with a first diagnosis of ALL or LBL 
(T-cell non Hodgkin lymphoma [TNHL] or Surface 
membrane immunoglobulin [SmIg] negative precursor 
B-cell non Hodgkin lymphoma [B-NHL]) diagnosed 
under standard criteria are eligible for BONES.
Exclusion criteria: inability to have MRI scans of lower 
limbs
recruitment target
The recruitment target is 50 patients over a 2-year period, 
which is based on an anticipated participation of 75% of 
eligible cases. Given the observational nature of the study, 
and the wide number of potential predictors of interest, a 
power calculation is of limited relevance and is difficult to 
calculate given the current lack of data. However, taking 
pubertal status as an example, assuming 60% of patients 
will be in puberty, the study would detect a risk ratio of 3 
with 82% power with a 5% level of significance.
study outcomes
Primary outcome
 ► Cumulative incidence of symptomatic and asymp-
tomatic osteonecrosis in patients aged between 10 
and <25 years being treated for ALL or LBL in the UK 
at multiple time points in their treatment.
Key secondary outcomes
 ► Risk factors for progression and development of symp-
tomatic osteonecrosis.
 ► Specific radiological features that predict for either 
progression or regression in those with osteonecrosis.
 ► Evaluation of functional ability as measured by 
CHAQ and physiotherapy assessment, with explora-
tion of correlation with radiological findings.
 ► Bone mineral density changes as measured by dual-en-
ergy X-ray absorptiometry (DXA) during treatment 
for ALL or LBL.
 ► Prevalence and risk factors for development of verte-
bral fractures during treatment for ALL or LBL.
Patient assessment
Irrespective of symptoms patients will be screened for 
osteonecrosis via prospective MRI of the hips, knees and 
ankles at the following time points:
 ► Within 4 weeks of diagnosis.
 ► At the end of delayed intensification (typically 6–8 
months after start of ALL treatment).
 ► One year after the start of maintenance.
 ► Two years after the start of maintenance.
 ► Three years after the start of maintenance.
Patients will also have a physiotherapy assessment at 
each of these time points, including subjective and objec-
tive assessments, with collection of clinical and biochem-
ical data.
Where facilities exist, DXA scans and vertebral fracture 
assessment will be performed at diagnosis and annually 
for 3 years after diagnosis.
Magnetic resonance imaging
MRI of the lower limbs including hips, knees and ankles 
comprises unenhanced coronal T1-weighted and short 
tau inversion recovery images of 5 mm (or less) slice 
thickness as a minimum protocol. Scanning parameters 
may vary slightly depending on available MR scanners in 
each participating centre.
It can be difficult to differentiate osteonecrosis from 
other abnormalities affecting the bone such as marrow 
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oedema, punctate foci of altered signal, haematopoietic 
marrow changes in children and, as we are imaging chil-
dren with ALL, early leukaemic marrow infiltration.51 
Osteonecrosis is defined as an area of yellow marrow 
surrounded by a low signal intensity rim on all pulse 
sequences or a double line rim comprising a low signal 
line and an adjacent high signal line on fluid sensitive 
sequences. The area of osteonecrosis may be complex 
in shape with serpentine, crescentic, band-like or undu-
lating outline or represented as multiple small lesions.52–54 
The presence of non-classical abnormalities will also be 
recorded if encountered, including haemorrhagic or 
cystic change as well as non-specific marrow changes and 
marrow oedema as these have been previously described 
and may represent significant prognostic factors.52–54
Clinical and demographic data collection
Baseline demographic data collection includes the child’s 
age, sex, ethnic background (white British; Asian; black; 
mixed; other), postcode, height and weight at diagnosis. 
Clinical data are provided by the treating clinicians via a 
dedicated clinical report form, which includes informa-
tion on pubertal status, highest white cell count prior to 
treatment, immunophenotype, cytogenetics and molec-
ular results, along with presence or absence of hepato-
megaly, splenomegaly, lymphadenopathy and bone pain 
at diagnosis.
At each of the time points outlined above, details 
regarding treatment regime, height, weight, phase of 
puberty and diagnosis and management of symptomatic 
osteonecrosis are collected. Data on results of routine 
blood tests, including lipid profile, albumin, bone profile, 
parathyroid hormone (PTH) and vitamin D levels is also 
collected. Clinicians collecting these details are blinded 
to the study MRI reports.
If a patient develops symptomatic osteonecrosis of 
upper or lower limbs, they will be managed as per local 
policy, but imaging results and clinical data will be 
collated.
Physiotherapy evaluation
The physiotherapy assessment consists of a paper ques-
tionnaire for completion by the participant, which 
includes information about activity levels, mobility, pain 
and the CHAQ, alongside a physical assessment evalu-
ating gait, range of movement and muscle power.55 The 
CHAQ assesses three outcome dimensions: disability, 
discomfort and pain and is completed by self-report, 
requiring approximately 10–15 min to complete. It is 
most commonly used to assess health status and physical 
function in children with juvenile arthritis, for whom it is 
validated,55 but is also validated for use in children with 
chronic musculoskeletal pain,56 dermatomyositis57 and 
systemic lupus erythematosus.58
Bone mineral density and vertebral fracture assessment
Patients will undergo DXA scans with vertebral fracture 
assessment with collection of the following measurements: 
posterior-anterior lumbar spine (L1-4) and total body less 
head (TBLH), bone mineral apparent density (BMAD) 
and thoracic and lumbar vertebral fracture incidence.
A schema with BONES study procedures is presented 
in figure 2.
data analysis plan
The report of this study will be prepared in accordance 
to guidelines set by the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) state-
ment for observational studies.59
A central review panel consisting of paediatric radiol-
ogists with an interest in paediatric musculoskeletal 
imaging will review each MRI. The grade of osteonecrosis 
will be assessed using a modified scoring system by refer-
ence using a study radiology pro forma.
We will be using the classification system published 
by Niinimäki et al50 to assess osteonecrosis in the lower 
legs. As this system is not joint specific, it can be used 
to assess hips, knees and ankles in the same way. Our 
study radiology proforma will also separately record 
osteonecrosis seen within the metaphysis and diaphysis 
of long bones. If different scores are seen for two bones 
comprising a joint (eg, tibial and femoral epiphysis as 
part of the knee), both scores will be captured before 
giving the overall score for the knee according to Niin-
imäki et al, with the aim to assess the overall burden of 
osteonecrosis in the limb.
DXA and vertebral fracture assessment results will also 
be reviewed centrally, with adjustments to bone mineral 
density using bone mineral adjusted density bone mineral 
apparent density (BMAD) for the spine, and the height 
Z-score for TBLH.60 The thoracic and lumbar vertebra 
will be assessed (T4-L4 where possible), using the Genant 
semiquantitative method.61
The information from the CHAQ will be numerically 
coded using the disability index, global evaluation and 
pain assessment. The physiotherapy assessment will also 
be numerically coded to score muscle power and range 
of movement for each individual joint. Qualitative state-
ments will be recorded and coded at the end of the study.
Data will be collected and analysed in clinically rele-
vant categories, while χ2 tests and multivariable logistic 
regression models will be used to determine differences 
between groups adjusting for a relevant set of confounders 
identified using causal inference methods.62 Potential 
confounders that will be assessed include age, sex, ethnic 
group, socioeconomic status (using the Index of Multiple 
Deprivation rank63), treatment arm, highest white cell 
count, immunophenotype, cytogenetics (categorised into 
risk groups as per the UKALL 2011 protocol), phase of 
puberty, BMI Z-score, lipids, albumin, presence of verte-
bral fractures, bone mineral density, bone alkaline phos-
phatase (ALP), PTH and vitamin D status. ORs will be 
used to describe size of observed associations with 95% 
CIs. If numbers are sufficiently robust, a more sophisti-
cated ordered logistic regression analysis will be carried 
out using an ordered categorical outcome variable for 
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severity of osteonecrosis, and risk of developing osteone-
crosis will be assessed using Poisson regression, using the 
same set of confounders and the risk estimates, quanti-
fied by incidence rate ratios and 95% CIs.
Data completeness and validity
We will carry out range checks on the variables listed:
 ► Albumin.
 ► HDL.
 ► LDL.
 ► Cholesterol.
 ► Triglycerides.
 ► PTH.
 ► Vitamin D.
 ► ALP.
 ► Calcium.
 ► Phosphate.
If data on some subjects are missing at some time points, 
the entire subject history will not simply be excluded 
from analysis. The main patient characteristics will be 
described in terms of variable completeness by summa-
rising the proportion of missing values. If numbers allow, 
levels of missingness will also be examined according to 
each recruiting centre. If the data are missing at rates 
higher than the expected attrition rate, the following 
steps will be taken:
 ► If data regarding independent variables are missing 
but data for the corresponding dependent variables 
are present, we will do multiple imputations for the 
missing values.
 ► If some data associated with a dependent variable are 
missing, such as some follow-up data, and the under-
lying mechanism is random, only the missing observa-
tions will be excluded.
 ► If some dependent variable data are missing and the 
underlying mechanism is non-random, we will esti-
mate group effects according to methods proposed by 
Wu and Bailey64 and Milliken and Johnson.65
Violations of the missing-at-random assumption will be 
investigated by following established precedents in paedi-
atric oncology studies.
data management
All patients enrolled in the study are given a unique iden-
tifier. A Microsoft Access database has been developed 
to record and link all the sociodemographic and clinical 
data for a study participant with information from their 
radiology assessments. Data protection regulations at 
Figure 2 Schema of BONES study procedures. BONES, British OsteoNEcrosis Study; CHAQ, Childhood Health Assessment 
Questionnaire; DXA, dual-energy X-ray absorptiometry; LFTs, liver function tests; LDL, low-density lipoprotein; HDL, high-
density lipoprotein.
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each centre will be complied with. Data will be submitted 
centrally via a secure National Health Service email 
address with all patient identifiers removed. At each 
hospital site, local clinicians and physiotherapists will 
complete the relevant forms at each time point, with 
forms anonymised locally prior to being returned to the 
central trial unit. Images of MRI scans are to be anony-
mised locally and placed onto CDs, which are to be sent 
to the central trial unit. DXA scan images and reports are 
to be anonymised locally and sent to the central trial unit.
At present, data are not published in a data repository.
The full protocol is available in online supplementary 
file 2. Sample consent forms and patient information 
sheets are available as online supplementary file 3.
Protocol amendments
All substantial protocol amendments will be agreed with 
the protocol contributors and require research ethics 
committee approval. Modifications will be communi-
cated to the relevant parties via the website, newsletters 
and email.
Ethics and dissemination
NHS code of confidentiality and data protection will be 
adhered to. All data acquisition, storage and transmission 
will comply with the Data Protection Act 1998. The local 
clinical team will identify and provide age-appropriate 
patient information sheets to potential participants. 
Written patient consent or assent will be obtained by the 
local clinical team, with parental consent obtained for 
patients under 16 years of age. The protocol document 
and data collection tools are available online (http:// 
childhealth. leeds. ac. uk/ bones. html). All substantial 
protocol contributors will be granted authorship of the 
final study report. There are no plans to use professional 
medical writers.
Collective results of the study will be published on the 
website, in peer-reviewed journals and presented at rele-
vant conferences and via social media.
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